(D) Statistic results of total distance of the cells that treated with PBS, 10 μM VLP H1 or VLP H2. (E) Statistic results of velocity

of the cells that treated with PBS, 10 μM VLP H1 or VLP H2. The 5-Fluoracil in vitro data are expressed as mean ± SEM of more than 60 cells from at least three independent experiments. Single asterisk (*) denotes P < 0.05 and double asterisk (**) P < 0.01 compared to control. (F) Migration tracks of 10 MDA-MB-231 cells that treated with PBS, 10 μM VLP H1 or VLP H2. To delineate whether VLP H1 and VLP H2 regulate the invasion of breast cancer cells, MDA-MB-231 cells were treated with 10 μM purified VLP H1, VLP H2, or PBS (as control). The invasion of these cells was measured by examining the functional capacities of the cells penetrating through transwell filters coated with 0.35 mg/ml Matrigel. VLP H1 and VLP H2 inhibited the invasion of MDA-MB-231 cells (Figure 3A). VLP H1 and VLP H2 inhibit tumor growth in animals To evaluate VLP H1 and VLP H2 therapeutic potential, we determined whether VLP H1 and VLP H2 inhibit MDA-MB231 tumor xenograft growth in nude mice. MDA-MB231 cells were implanted in nude mice. After tumors had established, mice were treated with 10 mg/kg of VLP H1 or VLP H2 (6 days per week) by intraperitoneal injection

for 3 weeks. VLP H1 and VLP H2 inhibited tumor growth, resulting in significantly reduced tumor volumes (Figure 4C). Indeed, the tumors in VLP H1- and VLP H2-treated mice were significantly smaller (Figure 4A), and 10 mg/kg of VLP H1 and VLP H2 {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| decreased the tumor mass by 64.58% and 41.36%, respectively Sinomenine (Figure 4B). Interestingly, VLP H1 and VLP H2 did not decrease mouse body weights (Figure 4D) – a result consistent with the notion that VLP H1 and VLP H2 preferably target tumor cells and thus exhibited little toxicity

to the animals. Taken together, we demonstrated that VLP H1 and VLP H2 inhibited tumor growth in vivo. Figure 4 VLP H1 and VLP H2 suppressed tumor growth in a xenograft model of human breast cancer. Female nude mice (5 to 6 weeks old) were injected subcutaneously with 1 × 106 MDA-MB231 breast cancer cells into the left and right mammary glands of each animal. Tumor size was measured daily or every other day with calipers, and tumor volumes were calculated using the formula: Volume = (width)2 × length/2. After the tumors had established, mice were treated with 10 mg/kg of VLP H1 or VLP H2 (6 days per week) by intraperitoneal injection for 3 weeks. VLP H1 and VLP H2 inhibited tumor growth (A), reduced mouse weight (B), and tumor volumes (C) but did not decrease mouse body weights (D). Discussion VLPs are multisubunit self-assembly competent protein structures with identical or highly related overall structure to their corresponding native viruses [22]. The term ‘VLP’ has been used to describe a GANT61 in vitro number of biological objects.